侵入性非转移性乳腺癌的生存风险评分:现实世界的分析
Lucia Mangone1, Fortunato Morabito2, Giovanni Tripepi3
1Epidemiology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
JCO global oncology
|October 31, 2024
概括
一个新的风险评分 (SRS_M0-BC) 有效地分层了患有非转移性侵入性乳腺癌的患者. 该工具使用常见的预后因素来预测整体存活率,帮助临床决策.
科学领域:
- 在瘤学瘤学.
- 生物统计学 生物统计学
- 癌症研究 癌症研究
背景情况:
- 准确的预后对于管理非转移性侵袭性乳腺癌 (M0-BC) 至关重要.
- 现有的模型可能无法完全捕捉到M0-BC的整体存活率 (OS) 预测的复杂性.
- 需要开发可访问和全球适用的风险分层工具.
研究的目的:
- 开发和验证一个多变量,加权的整体生存 (OS) 风险评分 (SRS),专门用于非转移性 (M0) 侵入性乳腺癌 (M0-BC).
- 创建一个预后工具 (SRS_M0-BC) 是低成本的,可访问的,并在日常临床实践中适用.
主要方法:
- 利用来自雷吉奥埃米利亚癌症登记处 (RE-CR) 的培训队列 (1890名患者) 和验证队列 (850名患者).
- 评估了十个传统的预后变量,开发了一个基于OS的显著预测因素的多变量模型.
- 根据危险比率 (HRs) 分配得分,以产生不同的风险类别.
主要成果:
- 雌激素受体状态,瘤阶段T2-T4和年龄>74岁与死亡风险增加有显著关联.
- 创建了四个风险类别,高风险患者的死亡率是低风险组的27.3倍,高风险患者的死亡率是低风险组的27.3倍.
- 开发的风险评分显示出强大的预测性能,Harrell'C指数在培训组中为81.1%,在验证组中为76.1%.
结论:
- 开发的多变量,加权的整体生存风险评分 (SRS_M0-BC) 有效地对侵袭性M0-BC患者进行了分层.
- 这种基于真实世界的数据的工具,为临床实践提供了一个低成本和全球适用的方法.
- SRS_M0-BC可以帮助临床医生预后分层患者,潜在地改善治疗决策和患者的治疗结果.
相关概念视频
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Comparing the Survival Analysis of Two or More Groups
155
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
155
Actuarial Approach
63
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
63
Kaplan-Meier Approach
102
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
102
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
121
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
121


